Pure Global AI
NCT06299592Recruiting

Comparison of Microglial Activation in Severe Asthma and Healthy Controls

University of Wisconsin, MadisonClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Asthma
Drug/Device/Intervention
PET/MRI using [18F]FEPPA tracer
Study type
Observational
Intervention type
combination product
Sponsor & location
Primary sponsor
University of Wisconsin, Madison
Location
Madison, United States of America
Timeline & enrollment
Phase
N/A
Start date
Mar 06, 2024
End date
Aug 01, 2028
Enrollment
100 participants
Primary outcome

Binding of [18F]-FEPPA

Summary

The goal of this clinical trial is to learn about how asthma influences brain function. The
 main questions it aims to answer are:
 
 - How airway inflammation in asthma affects the brain; and,
 
 - Whether airway inflammation in asthma is related to symptoms of depression and anxiety
 
 Over the course of 3 visits, participants will:
 
 - Complete questionnaires
 
 - Complete computer tasks
 
 - Undergo allergy skin test and breathing tests
 
 - Give two blood samples
 
 - Give a sputum sample
 
 - Complete brain imaging scans
 
 Researchers will compare results between participants with asthma, and participants who do
 not have asthma.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06299592
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06299592 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Wisconsin, Madison and is currently Recruiting. The study focuses on Asthma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.